AbbVie Prompts Patients to ‘take on’ Arthritis in First Rinvoq DTC Ad

From: FiercePharma

By: Beth Snyder Bulik

AbbVie Prompts Patients to ‘take on’ Arthritis in First Rinvoq DTC Ad

While Xeljanz still enjoys support from rheums given the drug’s seven-year commercial history, docs indicated Rinvoq as the most preferred JAK if only one were to be prescribed, citing safety, efficacy and breadth of data all as key advantages over Xeljanz,” Piper Jaffray analyst Christopher Raymond wrote…(read more).